Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Non-Small-Cell Lung Cancer (NSCLC) (EGFR m) & Drugs/Treatments

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

The current research direction for treating patients with EGFR mutations focuses on the following aspects: uncommon EGFR mutation subtypes, brain metastases, and EGFR TKI-based combination therapy.
Lu et al. 2022b Expert Opinion on Emerging Drugs 27(2): 111-126

Chemotherapy followed with osimertinib brings about the best disease-free survival.
Tian et al. 2022a Future Oncology 18: 2695-2707

TKIs such as ﬁrst (erlotinib and geﬁtinib), second (dacomitinib and [afatinib](brain…

References (Sources)

EGFR mutation-positive NSCLC: factors to consider when deciding 1st line therapy
Hulo et al. 2020 Exp Rev Anticancer Ther 20: 365-372
Review
Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials
Lu et al. 2022b Expert Opinion on Emerging Drugs 27(2): 111-126
Review
Geﬁtinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
Maemondo et al. 2010 N Engl J Med 362: 2380-2388
How can better identification of T790M help to inform treatment sequencing decisions in EGFR mutation-positive NSCLC?
Hochmair 2019
Overall survival in stage IV EGFR mutation‑positive NSCLC: Comparing ﬁrst‑, second‑ and third‑generation EGFR‑TKIs
Vaid et al. 2021 Int. J. of Oncology 58: 171-184
Review
Therapeutic Approaches for the Treatment of Epidermal Growth Factor Receptor Mutated Lung Cancer
Sanchala et al. 2018 Current Cancer Drug Targets 18: 773-791
Review
Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)
Tan et al. 2019a Expert Review of Anticancer Therapy 19: 431-435

AI Chat

7/1/2026

Chat with our artificial intelligence: